Literature DB >> 1446651

Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma.

H Bando1, T Sano, T Ohshima, C Y Zhang, R Yamasaki, K Matsumoto, S Saito.   

Abstract

Plasma growth hormone (GH) responses to various stimuli were examined in 21 patients with GH-producing pituitary adenomas, classified into three types by the immunohistochemistry of cytokeratin and the glycoprotein hormone alpha-subunit distribution. Seven type 1 adenomas were exclusively composed of cells in which the cytokeratin formed a dot-like pattern; they were chromophobic to hematoxylin and eosin (H&E), occasionally positive for GH, and almost completely negative for the alpha-subunit. Thirteen type 2 adenomas were composed of cells with cytokeratin that had a perinuclear distribution; they were eosinophilic to H&E, and diffusely positive for both GH and the alpha-subunit. One patient had a type 3 adenoma which had a mixed pattern of intracellular cytokeratin distribution and was chromophobic and eosinophilic to H&E. Clinically, type 1 is characterized by earlier onset, larger tumor size, and more frequent aggressive extension. Paradoxical GH responses to TRH and OGTT were seen in 1 of 6 patients (16.7%) of type 1 and 8 of 9 patients (88.9%) of type 2, and 0% of type 1 and 62.5% of type 2, respectively. Type 2 cases showed higher plasma GH response to GH-releasing hormone, and a tendency to greater suppression of plasma GH by bromocriptine compared with type 1. Octreotide acetate administration revealed that the nadir/basal ratio of plasma GH levels was 42.9 +/- 6.6% in type 1 and 13.5 +/- 5.8% in type 2. These results suggest that there is a pathophysiological difference between these two distinct types of GH-producing pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446651     DOI: 10.1507/endocrj1954.39.355

Source DB:  PubMed          Journal:  Endocrinol Jpn        ISSN: 0013-7219


  14 in total

Review 1.  Update on prognostic factors in acromegaly: Is a risk score possible?

Authors:  E Fernandez-Rodriguez; F F Casanueva; I Bernabeu
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

2.  Cytokeratin distribution and functional properties of growth hormone-producing pituitary adenomas.

Authors:  Toshiaki Sano; Shozo Yamada; Takashi Hi Rose; Kazuo Hizawa
Journal:  Endocr Pathol       Date:  1994-06       Impact factor: 3.943

3.  Growth hormone tumor histological subtypes predict response to surgical and medical therapy.

Authors:  Katja Kiseljak-Vassiliades; Nichole E Carlson; Manuel T Borges; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Janice M Kerr; Margaret E Wierman
Journal:  Endocrine       Date:  2014-08-17       Impact factor: 3.633

Review 4.  Clinical implications of growth hormone-secreting tumor subtypes.

Authors:  Katja Kiseljak-Vassiliades; Shibana Shafi; Janice M Kerr; Tzu L Phang; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Endocrine       Date:  2012-03-21       Impact factor: 3.633

5.  Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.

Authors:  Amy A Swanson; Dana Erickson; Diane Mary Donegan; Sarah M Jenkins; Jamie J Van Gompel; John L D Atkinson; Bradley J Erickson; Caterina Giannini
Journal:  Pituitary       Date:  2020-10-19       Impact factor: 4.107

6.  Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.

Authors:  Katja Kiseljak-Vassiliades; Mei Xu; Taylor S Mills; Elizabeth E Smith; Lori J Silveira; Kevin O Lillehei; Janice M Kerr; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Mol Cell Endocrinol       Date:  2015-09-21       Impact factor: 4.102

7.  Elucidating the Role of the Desmosome Protein p53 Apoptosis Effector Related to PMP-22 in Growth Hormone Tumors.

Authors:  Katja Kiseljak-Vassiliades; Taylor S Mills; Yu Zhang; Mei Xu; Kevin O Lillehei; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Endocrinology       Date:  2017-05-01       Impact factor: 4.736

8.  Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form.

Authors:  Abdulkader Obari; Toshiaki Sano; Kenichi Ohyama; Eiji Kudo; Zhi Rong Qian; Akiko Yoneda; Nasim Rayhan; Muhammad Mustafizur Rahman; Shozo Yamada
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

9.  Immunohistochemical detection of glycoprotein hormone alpha subunit in somatoprolactinic and pure somatotroph adenomas.

Authors:  M C Vantyghem; C Cortet; C Bauters; M H Gevaert; D Dewailly; J Lefebvre; M Mazzucca
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

10.  Growth hormone is a cellular senescence target in pituitary and nonpituitary cells.

Authors:  Vera Chesnokova; Cuiqi Zhou; Anat Ben-Shlomo; Svetlana Zonis; Yuji Tani; Song-Guang Ren; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.